Octopus Biosafety（MLOCT）株式概要オクトパス・バイオセーフティSAは、フランス国内および国際的な養鶏産業向けの移動型、自律型、インテリジェント、モジュール式ロボットの設計、製造、販売に従事している。 詳細MLOCT ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 最新の財務報告は1年以上前のものである 過去1年間で収益は41.3%減少しました +3 さらなるリスクすべてのリスクチェックを見るMLOCT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.194.4k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-2m662k2016201920222025202620282031Revenue €385.1kEarnings €35.8kAdvancedSet Fair ValueView all narrativesOctopus Biosafety SA 競合他社NSC GroupeSymbol: ENXTPA:ALNSCMarket cap: €26.5mBIO-UV GroupSymbol: ENXTPA:ALTUVMarket cap: €18.9mTrilogiqSymbol: ENXTPA:ALTRIMarket cap: €19.1mHydrogen-Refueling-SolutionsSymbol: ENXTPA:ALHRSMarket cap: €34.5m価格と性能株価の高値、安値、推移の概要Octopus Biosafety過去の株価現在の株価€0.1952週高値€0.5052週安値€0.13ベータ0.0111ヶ月の変化-6.00%3ヶ月変化9.94%1年変化40.30%3年間の変化-38.16%5年間の変化-82.26%IPOからの変化-98.75%最新ニュースNew Risk • Jun 03New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m).New Risk • Dec 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m).New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m).New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France最新情報をもっと見るRecent updatesNew Risk • Jun 03New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m).New Risk • Dec 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m).New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m).New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray Franceお知らせ • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence FranceNew Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$578k). Market cap is less than US$10m (€1.35m market cap, or US$1.45m).Is New 90 Day High Low • Dec 21New 90-day low: €1.45The company is down 52% from its price of €3.04 on 22 September 2020. The French market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: €2.70The company is down 23% from its price of €3.52 on 02 September 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 06New 90-day low: €2.80The company is down 26% from its price of €3.80 on 08 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is flat over the same period.Is New 90 Day High Low • Sep 18New 90-day low: €3.30The company is down 17% from its price of €4.00 on 19 June 2020. The French market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 7.0% over the same period.株主還元MLOCTFR MachineryFR 市場7D-14.5%-4.3%0.3%1Y40.3%-12.5%1.8%株主還元を見る業界別リターン: MLOCT過去 1 年間で-12.5 % の収益を上げたFrench Machinery業界を上回りました。リターン対市場: MLOCT過去 1 年間で1.8 % の収益を上げたFrench市場を上回りました。価格変動Is MLOCT's price volatile compared to industry and market?MLOCT volatilityMLOCT Average Weekly Movement13.3%Machinery Industry Average Movement5.9%Market Average Movement5.2%10% most volatile stocks in FR Market11.0%10% least volatile stocks in FR Market2.7%安定した株価: MLOCTの株価は、 French市場と比較して過去 3 か月間で変動しています。時間の経過による変動: MLOCTの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてFrenchの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19876Bertrand Vergnewww.octopusbiosafety.comオクトパス・バイオセーフティ社は、フランス国内および国際的な養鶏産業向けの移動型、自律型、インテリジェント、モジュール型ロボットの設計、製造、マーケティングに従事している。同社は、養鶏のための連続的なリター処理、環境および動物モニタリングソリューションであるXO、鳥の動きを維持し、床卵の数を減らすロボットであるT-MOOV、騒音や埃を出さずに、また装置を持ち上げて家禽に怪我をさせる危険もなくリターを維持するのに役立つ電動スカーファイヤーであるEasy-LITを提供している。同社は1987年に設立され、フランスのオーレーに本社を置いている。もっと見るOctopus Biosafety SA 基礎のまとめOctopus Biosafety の収益と売上を時価総額と比較するとどうか。MLOCT 基礎統計学時価総額€23.90m収益（TTM）-€659.11k売上高(TTM)€385.11k62.1xP/Sレシオ-36.3xPER（株価収益率MLOCT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MLOCT 損益計算書（TTM）収益€385.11k売上原価€721.41k売上総利益-€336.29kその他の費用€322.81k収益-€659.11k直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.0052グロス・マージン-87.32%純利益率-171.15%有利子負債／自己資本比率-83.4%MLOCT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 10:31終値2026/06/09 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Octopus Biosafety SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 03New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m).
New Risk • Dec 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m).
New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m).
New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).
お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France
New Risk • Jun 03New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m).
New Risk • Dec 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m).
New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m).
New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).
お知らせ • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France
お知らせ • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence France
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).
New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$578k). Market cap is less than US$10m (€1.35m market cap, or US$1.45m).
Is New 90 Day High Low • Dec 21New 90-day low: €1.45The company is down 52% from its price of €3.04 on 22 September 2020. The French market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: €2.70The company is down 23% from its price of €3.52 on 02 September 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 06New 90-day low: €2.80The company is down 26% from its price of €3.80 on 08 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is flat over the same period.
Is New 90 Day High Low • Sep 18New 90-day low: €3.30The company is down 17% from its price of €4.00 on 19 June 2020. The French market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 7.0% over the same period.
